Shares of Azenta, Inc. (NASDAQ:AZTA – Get Free Report) have been assigned a consensus rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $41.3333.
A number of equities analysts have recently commented on AZTA shares. Jefferies Financial Group lowered their price objective on shares of Azenta from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. TD Cowen reiterated a “hold” rating on shares of Azenta in a research report on Wednesday, February 4th. Needham & Company LLC reissued a “buy” rating and issued a $44.00 target price on shares of Azenta in a research note on Tuesday, March 17th. Wall Street Zen downgraded Azenta from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Zacks Research raised Azenta from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th.
Check Out Our Latest Stock Report on AZTA
Institutional Inflows and Outflows
Azenta Trading Down 2.5%
AZTA stock opened at $21.31 on Friday. The company’s 50 day moving average is $29.10 and its 200 day moving average is $31.48. The stock has a market cap of $981.54 million, a price-to-earnings ratio of -15.79 and a beta of 1.39. Azenta has a 1-year low of $19.93 and a 1-year high of $41.73.
Azenta (NASDAQ:AZTA – Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Azenta had a negative net margin of 10.34% and a positive return on equity of 1.43%. The company had revenue of $148.64 million during the quarter, compared to analysts’ expectations of $146.89 million. During the same period in the prior year, the business earned $0.08 earnings per share. The company’s revenue for the quarter was up .8% compared to the same quarter last year. As a group, sell-side analysts forecast that Azenta will post 0.53 EPS for the current fiscal year.
Azenta declared that its Board of Directors has authorized a share buyback plan on Wednesday, December 10th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 14.9% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Recommended Stories
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
